Physician profile
Scott A Davis
NPI 1447405998
$10,825.13
in general payments reported to CMS, 2019-2025
37 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,796 · 2020: $1,392 · 2021: $1,379 · 2022: $1,217 · 2023: $1,935 · 2024: $1,564 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,979 · Education: $62.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,979.08 |
| Education | $62.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,524.78 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,449.71 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $1,239.34 | 2019-2025 | |
| Novo Nordisk INC | $1,224.71 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $879.46 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Lilly USA, LLC | $510.64 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $419.86 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $409.01 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $383.36 | 2019-2023 | Belsomra, Steglatro |
| Amarin Pharma, INC. | $273.95 | 2019-2021 | |
| Amgen INC. | $224.97 | 2019-2023 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $224.26 | 2023-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $222.34 | 2022-2024 | Quviviq |
| Glaxosmithkline, LLC. | $209.32 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $174.34 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $145.48 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $144.42 | 2021-2022 | |
| Exact Sciences Corporation | $137.96 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $130.04 | 2020-2021 | |
| Allergan, INC. | $120.56 | 2019-2020 | |
| Astellas Pharma US INC | $113.41 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $100.14 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $76.17 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $67.21 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $61.57 | 2019-2023 | |
| Abbott Laboratories | $60.02 | 2019-2022 | |
| Nalpropion Pharmaceuticals LLC | $50.51 | 2019 | |
| Phathom Pharmaceuticals, INC. | $49.92 | 2023-2024 | Voquezna |
| Tris Pharma INC | $36.16 | 2024 | Dyanavel Xr |
| Sumitomo Pharma America, INC. | $33.44 | 2024-2025 | Gemtesa |
| Genentech USA, INC. | $32.61 | 2019 | |
| Inari Medical, INC. | $21.80 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Eisai INC. | $16.30 | 2020 | |
| Currax Pharmaceuticals LLC | $15.85 | 2022 | |
| Medtronic, INC. | $15.19 | 2025 | Intellis Adaptivestim |
| Atland Pharmaceuticals, LLC | $15.03 | 2025 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Dexcom, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.